AstraZeneca (AZN) Investor update summary

Strategic context and sustainability vision

• Emphasizes interconnectedness of human, societal, and planetary health, with climate change and nature loss impacting disease burden and healthcare delivery.

• Focus on climate and nature action, health equity, and health systems resilience as core pillars of sustainability impact.

• Sustainability is integrated into overall business strategy, emphasizing long-term value and trust.

• Commitment to responsible, ethical business practices and robust governance, guided by company values.

Climate and nature action and achievements

• Achieved an 88% reduction in Scope 1 and 2 emissions since 2015, aiming for 98% by end-2026; 11 sites have already met this goal.

• Over 80% of supplier spend is with companies having science-based targets; $500 million invested in next-gen inhaler propellants with near-zero global warming potential.

• Updated Scope 3 target: 35% reduction by 2030 versus 2019, aligned with business growth and $80 billion revenue ambition.

• AZ Forest target adjusted to 100 million trees by 2030, focusing on high-quality projects and aiming for a 50% waste circularity rate.

• 81% of the global car fleet is electric; water and waste reduced by 23% since 2015.

Health equity and access

• Over 40% of genomic data now comes from underrepresented populations, supporting broader patient benefit.

• Health education and screening programs have reached 49 million people since 2024; 156 million from underserved communities impacted.

• Health equity programs aim to reach 1 billion people by 2030, with 400 million from underserved groups, including those in low/middle-income countries and rare disease patients.

• More than 60 partnerships with NGOs through the Young Health Programme.

• Programs like Healthy Heart Africa have screened 80 million patients; partnerships expand newborn screening and lung health equity.